I-Mab (NASDAQ:IMAB) Q2 2023 Earnings Call Transcript

Unidentified Analyst: This is [indiscernible] from Citi Research, and thank you for taking my question. And I have two more questions. One, the first one is about the CD47 projects. And we know that the [Gilead and Bayer Oncology] (ph) just terminated their project due to limited efficacy. So could you give us more color on the efficacy gap between the Phase 2 and the Phase 3 trial? And we know the primary endpoint for our Phase 3 trial is overall survival. And can you comment more about the improvement in the ORR rate to the benefit of the [indiscernible]? And yeah, it’s the first question. And the second follow-up, the [indiscernible] project for — and for the — for our coming pivotal study, where the regulatory open green lights for single-arm pivotal study or it should be head-to-head Phase 3 study? Thank you.

Raj Kannan: So thank you for the question on lenzo and then uli as well. So let me just reiterate on the lenzo one, right? So we have seen the announcements from the CD47 targeting companies recently. And as we said, this was obviously a great interest to us in terms of the announcement itself and how that impacts our program. As we said before, I think it’s a little premature for us to think about a decision whether we should continue or stop the molecule development. I think we continue to enroll our ongoing Phase 3 study in China. We continue to believe that our molecule is differentiated. But as we said, we are also going to review the interim data. We’re going to look at the full data from these CD47 that have announced their trial termination fully and then meet with experts to be able to make an informed decision on CD47.

So that, I think, is a crux of how we’re thinking about our program. As we said, this is only in China. We are not progressing with lenzo anywhere else outside of China until we get that information in our hand. On the uli question, let me pass it on to John to address that question in particular.

John Hayslip: Thank you, Raj. So I’d just add regarding uliledlimab and the potential development pathways. We have the utmost respect for the regulatory agencies. Certainly, they have a challenging task and regulatory guidance changes from time to time. So at this point, we would not comment further regarding the specific regulatory pathway for uliledlimab until after we’ve reached alignment with the right regulators. And then we’ll speak further about it after that time.

Raj Kannan: Does that answer your question?

Unidentified Analyst: Yes. Thank you.

Tyler Ehler: Thank you. And with that, we’re running a little over time, so we will conclude today’s call. If there are any follow-up questions, please feel free to reach out to your local IR representative, and we’ll get back to you as quick as possible. Thank you, everyone, have a great day.

Raj Kannan: Thank you.